
Friday, September 28, 2018—The Food and Drug Administration (FDA) has approved galcanezumab-glnm (Emgality; Lilly, Indianapolis, IN) for the prevention of migraine in adults. Galcanezumab is available a…
October 2018—In this new column, we feature content from presenters at the 2018-2019 Philadelphia Neurological Society meetings.
October 2018—Neurologists need to understand the phenomenon of using psychedelic drugs for cluster-busting and advocate for appropriate research.
Monday, September 17, 2018—The Food and Drug Administration (FDA) has approved fremanezumab-vfrm (Ajovy; Teva Pharmaceutical Industries, Jerusalem, Israel) for prevention of migraine in adults. Fre…
Wednesday, September 12, 2018—An investigational drug application has been filed with the Food and Drug Administration (FDA) for BHV-3500 (Biohaven, New Haven, CT). This new compound is the first intranasa…
Thursday, September 06, 2018—Data from 2 phase 3 pivotal trials of rimegepant (Biohaven, New Haven, CT) for treatment of patients with migraine will be presented at the 17th Biennial Migraine Trust Intern…
Wednesday, September 05, 2018—In a small (n = 17 men), double-blind, placebo-controlled study using a counterbalanced within-subjects design, treatment of patients with chronic neuropathic pain with d…
September 2018—A roundtable discussion with Claudia A. Chiriboga, MD, MPH; Jeffrey L. Cummings, MD, ScD; and Nir Lipsman, MD, PhD
For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com
Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.
We use cookies to offer a better user experience and to analyze site traffic. To comply with the European General Data Protection Regulation (GDPR), we are implementing a cookie consent manager to provide residents of the EU/EEA with the ability to customize their cookies. Until this is available, your continued use of this site will be deemed as consent to use of cookies.
Continue »